Biological and clinical review of stromal tumors in the gastrointestinal tract
- PMID: 11005253
- DOI: 10.14670/HH-15.1293
Biological and clinical review of stromal tumors in the gastrointestinal tract
Abstract
Submucosal tumors of the gastrointestinal tract (GI tract) mainly consist of gastrointestinal mesenchymal tumors (GIMTs) that are distributed in the GI tract from the esophagus through the rectum. GIMTs include myogenic tumors, neurogenic tumors and gastrointestinal stromal tumors (GISTs). The term "GIST" is now preferentially used for the tumors that express CD34 and KIT. GIMTs are composed of spindle or epithelioid cells, and 20% to 30% show malignant behavior, including peritoneal dissemination and hematogenous metastasis. KIT expression and mutations in the c-kit gene are found only in GISTs, but not in myogenic or neurogenic tumors. Mutation in the c-kit gene is associated with aggressive features and poor prognosis, and malignant GISTs frequently have mutations in the c-kit gene. The clinicopathological features of GISTs with or without c-kit mutations are markedly different. Therefore, GIMTs may be divided into four major categories based on histochemical and genetic data: myogenic tumors; neurogenic tumors; GISTs with c-kit mutation; and GISTs without c-kit mutation. The origin of GISTs is not fully understood. However, phenotypical resemblance to the interstitial cells of Cajal (ICCs) and gain-of-function mutations in the c-kit gene may suggest origin from ICCs and/or multipotential mesenchymal cells that differentiate into ICCs.
Similar articles
-
Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51. doi: 10.1016/s0959-8049(02)80602-5. Eur J Cancer. 2002. PMID: 12528772 Review.
-
Clinicopathological features of gastric stromal tumors.J Exp Clin Cancer Res. 2000 Dec;19(4):417-25. J Exp Clin Cancer Res. 2000. PMID: 11277317
-
Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.Virchows Arch. 2001 Jan;438(1):1-12. doi: 10.1007/s004280000338. Virchows Arch. 2001. PMID: 11213830 Review.
-
Gastrointestinal stromal tumors: recent advances in understanding of their biology.Hum Pathol. 1999 Oct;30(10):1213-20. doi: 10.1016/s0046-8177(99)90040-0. Hum Pathol. 1999. PMID: 10534170 Review.
-
Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor.Dig Surg. 2003;20(3):183-91. doi: 10.1159/000070384. Dig Surg. 2003. PMID: 12759497
Cited by
-
Neoplasms associated with germline and somatic NF1 gene mutations.Oncologist. 2012;17(1):101-16. doi: 10.1634/theoncologist.2010-0181. Epub 2012 Jan 12. Oncologist. 2012. PMID: 22240541 Free PMC article. Review.
-
A gist of gastrointestinal stromal tumors: A review.World J Gastrointest Oncol. 2013 Jun 15;5(6):102-12. doi: 10.4251/wjgo.v5.i6.102. World J Gastrointest Oncol. 2013. PMID: 23847717 Free PMC article.
-
Small submucosal tumors of the stomach: differentiation of gastric schwannoma from gastrointestinal stromal tumor with CT.Korean J Radiol. 2012 Jul-Aug;13(4):425-33. doi: 10.3348/kjr.2012.13.4.425. Epub 2012 Jun 18. Korean J Radiol. 2012. PMID: 22778564 Free PMC article.
-
STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1.Cancer Sci. 2005 Feb;96(2):116-9. doi: 10.1111/j.1349-7006.2005.00018.x. Cancer Sci. 2005. PMID: 15723656 Free PMC article.
-
STI571 (Glivec) suppresses the expression of vascular endothelial growth factor in the gastrointestinal stromal tumor cell line, GIST-T1.World J Gastroenterol. 2006 Feb 7;12(5):703-8. doi: 10.3748/wjg.v12.i5.703. World J Gastroenterol. 2006. PMID: 16521182 Free PMC article.